Abstract:OBJECTIVE:Aplastic anemia is characterized by bone marrow failure and marked reduction of white blood cells, red blood cells and platelets in peripheral blood. Clinical studies have shown that immunosuppressive therapy greatly prolonged the long-term survival of some patients with aplastic anemia. But in severe aplastic anemia (SAA) patients whose ANC was < 0.5 x 10(9)/L, platelets were < 20 x 10(9)/L, very low bone marrow proliferation and high death rate were observed. The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA. METHODS:Fifty-four cases with SAA were treated with immunosuppressive agents mentioned above in our department from Jan. 1997 to June 2003, 31 of the cases had treated with CSA combined with ATG. There were 18 cases with SAA type I and 13 cases with SAA type II in CSA combined with ATG group, and 13 cases had very severe aplastic anemia. The other 23 cases were treated with CSA alone (CSA group), 10 of these cases had SAA-I and 13 had SAA-II, and 5 cases had very severe aplastic anemia. The responsive rate, relapse, adverse reactions and event free survival (EFS) were compared between CSA combined with ATG group and CSA group. RESULTS:The proportions of patients with different types of the disease and severity were comparable between the two groups. The responsive time of the CSA combined with ATG group and CSA group was 2.5 months and 3.5 months, respectively (P < 0.05), the responsive rate in two groups was 81% (25/31) and 52% (12/23), respectively (chi(2) = 4.962, P < 0.05). In 37 cases who were responsive to therapy, the relapse rate was 8% (2/25) and 50% (6/12) respectively (chi(C)(2) = 6.143, P < 0.05). There were no significant differences in adverse reactions to the immunosuppressive agents. All cases were followed-up for more than 1 year, and the event-free survival over one year in these two groups was 81% (25/31) and 52% (12/23), respectively. Forty-seven cases were followed-up for more than two years, and the event-free survival was 74% (20/27) and 50% (10/20), respectively (P < 0.01). Twelve cases were followed-up for over 5 years. There were no secondary tumor, myelodysplastic syndrome and other colony diseases. CONCLUSION:The immunosuppressive therapies for acquired severe aplastic anemia in childhood were effective. The effect of CSA combined with ATG was better than that of CSA alone, and the relapse rate was lower with the combined treatment. However, the long-term effect needs longer follow-up studies to evaluate.

Clinical analysis of childhood hepatitis associated aplastic anemia

Clinical features of hepatitis associated aplastic anemia for children by eviden ce-based medical analysis

[Clinical features of hepatitis-associated aplastic anemia in children].

Clinical Analysis of Hemopathy Patients with HBV Infection

Clinical Features and Treatment Outcome of Hepatitis Associated Aplastic Anemia in 43 Children

Clinical analysis of immunosuppressive therapy in childhood aplastic anemia

[Long-Term Follow-up of Patients with Hepatitis-Associated Aplastic Anemia].

Effectiveness of Immunosuppressive Therapy for Childhood Aplastic Anemia and Its Predictive Factors

Comparable Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hepatitis-Associated Aplastic Anemia and Non-Hepatitis-associated Aplastic Anemia.

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia

Therapeutic effects of a combination of high-dose immunoglobulin and cyclosporine A in children with aplastic anemia

Treatment of aplastic anemia with intensive immunosuppressive agents in children

Outcome of 64 Aplastic Anemia Children with Allogenic Hematopoietic Stem Cell Transplant in China: A Report from Chinese Pediatric Group of HSCT

Clinical Analysis of 85 Cases with Aplastic Anemia

The change of CD5~+B lymphocytes in the peripheral blood of patients with childhood aplastic anemia and its clinical significance

Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation

[Haploidentical hematopoietic stem cell transplantation in the treatment of acquired aplastic anemia in children: a single center retrospective analysis]

Clinical characteristics and classification of pediatric aplastic anemia

Natural history of moderate aplastic anemia in children and effects of immunosuppresstve therapy

[Immunosuppressive therapy for 54 children patients with acquired severe aplastic anemia].

Evaluation on the therapeutic efficacy of the combined immunosuppression therapy in children with aplastic anemia